{"id":237310,"date":"2026-09-09T12:22:54","date_gmt":"2026-09-09T06:52:54","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=237310"},"modified":"2026-09-09T12:22:54","modified_gmt":"2026-09-09T06:52:54","slug":"is-balaxi-pharmaceuticals-a-good-buy-after-q1-fy27-results","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/is-balaxi-pharmaceuticals-a-good-buy-after-q1-fy27-results\/","title":{"rendered":"Is BALAXI PHARMACEUTICALS a Good Buy After Its Q1 FY27 Results?"},"content":{"rendered":"

BALAXI PHARMACEUTICALS share price around Rs 24. 50.4% below 52-week high of Rs 48. Q1 FY27 revenue Rs 80 crore, up 15.6% YoY. PAT Rs 1.30 crore, up 348.3%. PE 53x.<\/em><\/p>\n

\n

Quick Answer<\/strong><\/p>\n

BALAXI PHARMACEUTICALS’s Q1 FY27 results were strong, with revenue at Rs 80 crore and PAT climbing 348% to Rs 1.30 crore. The stock trades at a PE of 53x against an industry average near 38x, so some of this good news is already priced in. The BALAXI PHARMACEUTICALS share price near Rs 24 reflects that optimism, so investors weighing whether BALAXI PHARMACEUTICALS is a good buy today should focus on whether this pace of growth can be sustained rather than just this quarter’s print.<\/p>\n<\/p><\/div>\n

The BALAXI PHARMACEUTICALS share price has been under the spotlight this results season after the company reported its first-quarter numbers for FY27. BALAXI PHARMACEUTICALS is a pharmaceutical company focused on exports and distribution to emerging markets, and its Q1 FY27 print, for the quarter ended June 30, 2026, gives investors a fresh data point to test whether the stock still deserves a place in a portfolio at current levels.<\/p>\n

Revenue for the quarter came in at Rs 80 crore, up 15.6% year on year, while profit after tax came in at Rs 1.30 crore, up 348.3% from a year earlier. That combination of numbers is exactly what this article breaks down, along with what it means for the BALAXI PHARMACEUTICALS share price from here.<\/p>\n

This piece works through the quarter’s financial highlights, the business factors behind the numbers, where the BALAXI PHARMACEUTICALS share price stands against its 52-week range and valuation multiples, and the key risks worth watching before treating this as a buy, hold or a stock to avoid for now.<\/p>\n

Click Here – Get Free Investment Predictions<\/strong><\/a><\/p>\n

\n
\n

Table of Contents<\/p>\nToggle<\/span><\/path><\/svg><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n